


# Hematopoietic Stem Cells Differentiation

**Hematopoietic stem cells (HSCs)** are the basis of hematopoiesis, or the process by which undifferentiated cells propagate mature blood cell lineages. Through hematopoiesis, hundreds of billions of blood cells are produced daily in order to maintain normal blood circulation. HSCs are rare, multipotent, self-renewing cells that are mainly found in the bone marrow, but can also be found in umbilical cord blood and peripheral blood. HSCs are non-homogeneous and can be divided into two populations of either long-term self-renewing cells, which are ideal for transplantation or short-term self-renewing cells. Additionally, HSCs can also be categorized based on their biases towards lymphoid and myeloid lineages: separating into those that produce a balance of lymphoid and myeloid cells, those that produce very few lymphoid cells, and those that produce very few myeloid cells.



# Hematopoietic Stem Cells Differentiation (continued)

HSCs undergo a series of changes in order to produce the mature blood cells found in circulation. These progeny gradually lose their capabilities of self-renewal, becoming more restricted in their differentiation potential and generating lineage-committed progenitor cells.

The proliferation, self-renewal and differentiation of HSCs into various blood cells is dependant on the involvement of certain cytokines and growth factors. Stem cell factor (SCF) and Thrombopoietin (TPO), for example, have been found to be important factors in the development and self-renewal of HSCs. While Interleukins, such as IL-2, IL-3, IL-4, IL-6, IL-7, and IL-12, influence proliferation and maturation, colony-stimulating factors (CSFs), including granulocyte CSF (G-CSF), macrophage CSF (M-CSF) and granulocyte-macrophage CSF (GM-CSF), specifically stimulate differentiation of HSCs into committed cells.

In addition to cytokines and growth factors, small-molecules are becoming an important tool in stem cell research and application, as demonstrated by several studies examining their potential in manipulating HSCs. Current studies focus mainly on the issue of HSC *ex vivo* expansion. Several small molecules have been shown to effect various aspects of HSC expansion including self-renewal, apoptosis inhibition and differentiation inhibition. Some examples include increase self-renewal by UM171, SR1, P18IN003, BIO and Garcinol, the inhibition of differentiation by DEAB and the inhibition of apoptosis by zVADfmk and 5-HT.

Decades of research have established that, upon transplantation, HSCs have the ability to entirely reconstitute the hematopoietic system. They are currently the only type of stem cell used regularly in clinical applications. HSC transplantation is most commonly used to replenish hematopoietic systems destroyed by chemotherapy or radiation therapy during treatment of patients with blood or bone marrow malignancies. The HSCs that are used for transplantation are derived from bone marrow, peripheral blood or umbilical cord blood, and can be either autologous (the patient's own cells) or allogeneic (from a genetically matched donor). Allogeneic HSC transplantation is still considered a dangerous procedure due to various associated complications, such as graft-versus-host disease, infections, mucosistis, veno-occlusive disease and the development of new malignancies.

Although HSC transplantation is well established, there are still many remaining challenges that need to be addressed in order to optimize success. These challenges include improving the access of HSC transplantation to patients in less developed countries, bettering the understanding of the immunological basis behind graft rejection and graft-versus-host disease, and identifying both new sources of HSCs and new techniques for obtaining sufficient cell numbers.

Investigating into HSC applications have recently branched into new avenues, namely clinical gene editing therapy, which have suggested the possibility of differentiating HSCs into mature cells across germ layers. Although these studies are still in the initial stages, they introduce the possibility of using HSCs in regenerative treatment of non-hematopoietic systems.

## Additional reading:

1. Eaves, C. J. (2015). Hematopoietic stem cells: concepts, definitions, and the new reality. *Blood*, 125(17), 2605-2613.
2. Laurenti, E., & Göttgens, B. (2018). From haematopoietic stem cells to complex differentiation landscapes. *Nature*, 553(7689), 418-426.
3. Müller, A. M., Huppertz, S., & Henschler, R. (2016). Hematopoietic stem cells in regenerative medicine: astray or on the path?. *Transfusion Medicine and Hemotherapy*, 43(4), 247-254.
4. Park, B., Yoo, K. H., & Kim, C. (2015). Hematopoietic stem cell expansion and generation: the ways to make a breakthrough. *Blood research*, 50(4), 194-203.
5. Zhang, Y., & Gao, Y. (2016). Novel chemical attempts at ex vivo hematopoietic stem cell expansion. *International journal of hematology*, 103(5), 519-529.



5 Crescent Avenue  
P.O. Box 275  
Rocky Hill, NJ 08553

Ph: 800.436.9910  
Fax: 609.497.0321

[info@peprotech.com](mailto:info@peprotech.com)  
[www.peprotech.com](http://www.peprotech.com)